Showing 2561-2570 of 3039 results for "".
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- Zeiss Celebrates 175th Anniversary in 2021https://modernod.com/news/zeiss-celebrates-175th-anniversary-in-2021/2479194/Zeiss’ success story began 175 years ago, in a small workshop. On November 17, 1846, young mechanic Carl Zeiss opened his workshop for precision mechanics and optics in Jena, thus laying the foundation for what would become today’s global technology player Zeiss. Zeiss went on to join
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Belkin Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Secondshttps://modernod.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds-2/2479186/Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, noninferiority, observer masked RCT a total of 192 patients were randomized across two arms, SLT and DSLT. Six-month follow up for primary endpoint is expected
- Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bankhttps://modernod.com/news/eyenovia-announces-new-25-million-credit-facility-with-silicon-valley-bank/2479182/Eyenovia announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB). “This non-dilutive credit facility provides us with a significant amount of financial and operating flexibility at terms that we
- Rayner’s RayOne Aspheric preloaded IOL launches in Chinahttps://modernod.com/news/rayners-rayone-aspheric-preloaded-iol-launches-in-china/2479183/Rayner announced that its RayOne Aspheric fully preloaded IOL injection system has been approved by the Chinese regulator, National Medical Products Administration (NMPA), and is now available for commercial use in China. The NMPA granted regulatory approval and sale of the 6.0 mm RayOne A
- Tarsus Pharmaceuticals Initiates Saturn-2 Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-initiates-saturn-2-phase-3-trial-evaluating-the-safety-and-efficacy-of-tp-03-for-the-treatment-of-demodex-blepharitis/2479179/Tarsus Pharmaceuticals announced that it has commenced enrollment in Saturn-2, its second pivotal trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis. Up to 25 million Americans may be affected by Demodex blepharitis, which is caused by an i
- Belkin Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Secondshttps://modernod.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds/2479174/Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, non-inferiority, observer-masked RCT, a total of 192 patients were randomized across two arms, SLT and DSLT. 6-month follow-up for primary endpoint is ex
- Eversight Names Diane Hollingsworth President/CEOhttps://modernod.com/news/eversight-names-diane-hollingsworth-president-ceo/2479171/Eversight announced that Diane Hollingsworth has been named President/CEO of the nonprofit eye bank network, effective immediately. Ms. Hollingsworth has served as interim President/CEO s
- Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-fulfills-post-marketing-approval-requirements-for-resure-sealant/2479164/Ocular Therapeutix has received notification from the FDA confirming it has fulfilled all post-approval study requirements for ReSure Sealant, with a requirement to update the ReSure label reflecting the study results. As a condition for ReSure’s pre-market approval application (PMA) in 2014, the